Cardiac myosin inhibitor sustainably reduces LVOT gradient in HCM

Name: Cardiac myosin inhibitor sustainably reduces LVOT gradient in HCM
Uploaded: 2022-04-04T02:00:00+00:00
Duration: 3 min 47 s
Description: ACC 2022 Maya Guglin explains the pathophysiology of hypertrophic cardiomyopathy (HCM) and discusses what the results of the long term extension study of E

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Moving the Needle in oHCM: The Era of Cardiac Myosin Inhibitors
Moving the Needle in oHCM: The Era of Cardiac Myosin Inhibitors
CME/CE
Moving the Needle in oHCM: The Era of Cardiac Myosin Inhibitors
Nosheen Reza, MD; Anjali Tiku Owens, MD
0.50 credits
- Nosheen Reza, MD
- Anjali Tiku Owens, MD
- Pieter Martens, MD, MSc, PhD
0.50 credits
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
ACC 2026 Clinical Insights: Advancing Cardiovascular Care
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Joseph Rossano, MD
- Joseph Rossano, MD
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Hypertrophic Cardiomyopathy
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Ahmad Masri, MD, MS
- Ahmad Masri, MD, MS
Aficamten improves peak oxygen uptake in obstructive HCM
Aficamten improves peak oxygen uptake in obstructive HCM
Hypertrophic Cardiomyopathy
Aficamten improves peak oxygen uptake in obstructive HCM
Caroline Coats, MD
- Caroline Coats, MD

Cardiac myosin inhibitor sustainably reduces LVOT gradient in HCM

Recommended

Title